Anesthesia, Renal Failure Chronic, Transplant;Failure,Kidney
Conditions
Keywords
Continuous spinal anesthesia, General anesthesia, Renal transplantation, Chronic renal failure
Brief summary
Renal transplantation is now recognized as a treatment of choice for patients with end-stage renal disease. An adequate anesthetic technique should achieve hemodynamic stability and enhance perfusion of the transplanted kidney. The aim of this study is to assess the use & effects of continuous spinal anesthesia for kidney transplantation recipients, compared with balanced general anesthesia.
Interventions
PROCEDUREContinuous spinal anesthesia
Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
PROCEDUREGeneral anesthesia
Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
Sponsors
Nazmy Edward Seif
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Using computer & sealed envelope randomization, patients are assigned to receive either continuous spinal anesthesia \[CSA group: n =30\] or general anesthesia \[GA group: n=30\]
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* ASA class III or IV * End-stage renal disease * Renal transplantation candidate patients
Exclusion criteria
* Any condition contra-indicating regional anesthesia * Coagulopathy * Allergic to any of the drugs used during the procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean ABP | 12 hours | Change in Mean Arterial Blood Pressure measured in mmHg. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Score for pain VAS | 12 hours | Visual Analogue Score for pain measures the degree of pain experienced by the patient during the procedure. VAS is graded from 0-10 \[where 0=no pain, 10= worst pain\]. |
| Patient satisfaction score | 24 hours | Patient satisfaction Score defines the degree of patient satisfaction with the anesthetic experience and is assessed after recovery. It is graded as excellent E (best score), fair F or poor P (worst score). |
Countries
Egypt
Outcome results
None listed